Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 1997

View Archived Issues

Fujisawa presents selective, nonpeptide thrombin receptor inhibitor

Altarex and Orgenics enter diagnostic development collaboration

Immunostimulants from Takeda

Hisamitsu claims novel antiallergic agents

New cephalosporins from Kyoto Pharmaceutical Industries

Sagami prepares angiotensin IV agonists

Cell migration inhibitors from Teijin

Nippon Shinyaku discloses cell adhesion inhibitors

Phase III results for HNK20

Promising phase II data presented for Novastan in acute MI

DU-6859a and liver dysfunction

3-D structure of adenylyl cyclase core determined

Freeze-dried fibrin-antibiotic complex for osteomyelitis

U.S. researchers discover protein that inhibits apoptosis

Xenova and Zeneca enter drug discovery collaboration

FDA clears midazolam for use in children

Byk Canada begins operations

FDA clears Skelid

Gene responsible for congenital glaucoma discovered

Terrapin Technologies provides overview of new and existing agreements

IBEX Technologies announces its results for the quarter ended January 1997

Texas Biotechnology reports fourth-quarter financial results

Amgen updates clinical progress and new research programs

Organogenesis Inc. announces fourth-quarter and year-end results for 1996

Diovan introduced in U.S.

Multikine trial approved in Israel

Lilly to discontinue or alter rHb1.1 collaboration with Somatogen

Matrix files NDA ammendment for AccuSite

Quadramet enters phase I for arthritis

RPR files for U.S. approval of CFC-free asthma inhalater

Preliminary phase I results for annamycin

Targretin enters phase II for diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...